SUBSCRIBE
SUBSCRIBE

Nimbus Therapeutics

NEWS
Drug Development
Is NASH Really a $35 Billion Opportunity?
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
September 25, 2018
 · 
4 min read
 · 
Karl Thiel
Drug Development
Navitor Appoints New CEO
Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.
August 3, 2018
 · 
3 min read
 · 
Mark Terry
Business
HotSpot Therapeutics Emerges From Stealth Mode With $45 Million to Aim at New Biological Targets
HotSpot Therapeutics burst forth from stealth mode with $45 million in Series A funding to support the development of therapies that will target natural “regulatory hotspots.”
July 17, 2018
 · 
2 min read
 · 
Alex Keown
Pictured: Pile of money/iStock, Ihor Lukianenko
Biotech Beach
Metacrine Closes $65 Million Series C Round
Metracrine, based in San Diego, completed a Series C financing round worth $65 million.
June 6, 2018
 · 
3 min read
 · 
Mark Terry
Genetown
Nimbus Therapeutics Raises Another $65 Million from Lilly, Bill Gates, Pfizer and Others
Nimbus Therapeutics, raised an additional $65 million in financing.
June 5, 2018
 · 
3 min read
 · 
Mark Terry
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Genetown
MA Life Science Growing: Backed By Eli Lilly and Pfizer, Nimbus Therapeutics Bankrolls $43 Million
March 18, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
January 6, 2026
 · 
2 min read
Press Releases
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
December 22, 2025
 · 
3 min read
Press Releases
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
April 28, 2025
 · 
4 min read
Press Releases
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
March 10, 2025
 · 
3 min read
Press Releases
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
February 25, 2025
 · 
2 min read
Press Releases
Nimbus Therapeutics Announces Clinical Progress in Oncology Therapeutic Pipeline and Provides Business Updates
January 9, 2025
 · 
4 min read
Press Releases
Nimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39th Annual Meeting
November 7, 2024
 · 
5 min read
News
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
October 23, 2024
 · 
4 min read
Press Releases
Nimbus Therapeutics to Present First Preclinical Data from Werner Syndrome Helicase Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 9, 2024
 · 
1 min read
Drug Development
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
May 23, 2024
 · 
4 min read
Load More